Summit Trail Advisors’s Galectin Therapeutics GALT Stock Holding History

Summit Trail Advisors’s Portfolio GALT Stock Details GALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$92.8K	Hold	20,000	–	–	﹤0.01%	1457
2026 Q1	$55.8K	Hold	20,000	–	–	﹤0.01%	1429
2025 Q4	$83.2K	Hold	20,000	–	–	﹤0.01%	1293
2025 Q3	$84.7K	Hold	20,000	–	–	﹤0.01%	1333
2025 Q2	$42.2K	Buy	+20,000	New	+$29.9K	﹤0.01%	1110
2024 Q4	–	Sell	-20,000	Closed	-$55K	–	524
2024 Q3	$55K	Hold	20,000	–	–	﹤0.01%	710
2024 Q2	$45.2K	Hold	20,000	–	–	﹤0.01%	609
2024 Q1	$47.8K	Hold	20,000	–	–	﹤0.01%	594
2023 Q4	$33.2K	Hold	20,000	–	–	﹤0.01%	551
2023 Q3	$38.4K	Hold	20,000	–	–	﹤0.01%	539
2023 Q2	$28.8K	Buy	+20,000	New	+$33.9K	﹤0.01%	538
2022 Q4	–	Sell	-23,855	Closed	-$39K	–	410
2022 Q3	$39K	Hold	23,855	–	–	﹤0.01%	372
2022 Q2	$31K	Hold	23,855	–	–	﹤0.01%	379
2022 Q1	$38K	Buy	+23,855	New	+$46.2K	﹤0.01%	321

Other funds holding GALT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

WANY

Wealthspire Advisors (New York) New York $18.2B AUM 21.48% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Summit Trail Advisors's GALT Position: Q2 2026 in Review

Summit Trail Advisors held its Galectin Therapeutics (GALT) position steady in Q2 2026 at 20,000 shares worth $92.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1457.

Summit Trail Advisors first reported a position in GALT in Q1 2022 and has held it in 14 quarters since. 98 funds tracked by Wall St. Rank hold GALT as of Q2 2026.

Summit Trail Advisors held 20,000 shares of Galectin Therapeutics worth $92.8K as of Q2 2026.
Summit Trail Advisors left its Galectin Therapeutics share count unchanged in Q2 2026.
Galectin Therapeutics made up ﹤0.01% of Summit Trail Advisors's portfolio in Q2 2026, its #1457 holding.
Summit Trail Advisors first reported a position in Galectin Therapeutics in Q1 2022 and has held it in 14 quarters since.
98 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q2 2026.

Based on Summit Trail Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.